Amgen Inc. $AMGN Shares Sold by Vestcor Inc

Vestcor Inc reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 8.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 29,486 shares of the medical research company’s stock after selling 2,640 shares during the period. Vestcor Inc’s holdings in Amgen were worth $8,321,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Sequoia Financial Advisors LLC raised its position in Amgen by 2.3% in the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after acquiring an additional 3,619 shares in the last quarter. Davis Capital Management bought a new position in shares of Amgen during the 3rd quarter valued at about $1,841,000. D.A. Davidson & CO. boosted its position in shares of Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after purchasing an additional 6,222 shares in the last quarter. Global Wealth Management Investment Advisory Inc. grew its stake in shares of Amgen by 56.2% in the 3rd quarter. Global Wealth Management Investment Advisory Inc. now owns 13,056 shares of the medical research company’s stock worth $3,684,000 after purchasing an additional 4,699 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its stake in shares of Amgen by 18.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 39,778 shares of the medical research company’s stock worth $10,888,000 after purchasing an additional 6,115 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of several research reports. Oppenheimer set a $400.00 price target on Amgen and gave the company an “outperform” rating in a report on Thursday, January 29th. Rothschild & Co Redburn lifted their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Citigroup boosted their target price on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. UBS Group upped their target price on Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a report on Monday, January 26th. Finally, TD Cowen reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $354.17.

Amgen Trading Up 2.0%

Shares of AMGN stock opened at $376.97 on Tuesday. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The company has a market cap of $203.21 billion, a PE ratio of 26.49, a price-to-earnings-growth ratio of 3.67 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The business’s 50 day moving average is $354.21 and its two-hundred day moving average is $323.38.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s dividend payout ratio is currently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.